Jundishapur Journal of Microbiology

Published by: Kowsar

In Vitro and in Vivo Antistaphylococcal Activity Determination of the New Recombinant Lysostaphin Protein

Hamid Abtahi 1 , Leila Farhangnia 2 and Ehsanollah Ghaznavi-Rad 3 , *
Authors Information
1 Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak, IR Iran
2 Department of Biotechnology, Faculty of Medicine, Arak University of Medical Sciences, Arak, IR Iran
3 Department of Microbiology and Immunology, Molecular and Medicine Research Center, Faculty of Medicine, Arak University of Medical Sciences, Arak, IR Iran
Article information
  • Jundishapur Journal of Microbiology: March 01, 2016, 9 (3); e28489
  • Published Online: March 2, 2016
  • Article Type: Research Article
  • Received: March 7, 2015
  • Revised: May 31, 2015
  • Accepted: June 14, 2015
  • DOI: 10.5812/jjm.28489

To Cite: Abtahi H, Farhangnia L, Ghaznavi-Rad E. In Vitro and in Vivo Antistaphylococcal Activity Determination of the New Recombinant Lysostaphin Protein, Jundishapur J Microbiol. 2016 ; 9(3):e28489. doi: 10.5812/jjm.28489.

Abstract
Copyright © 2016, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998; 339(8): 520-32[DOI][PubMed]
  • 2. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control. 1996; 24(5): 380-8[PubMed]
  • 3. Kumar JK. Lysostaphin: an antistaphylococcal agent. Appl Microbiol Biotechnol. 2008; 80(4): 555-61[DOI][PubMed]
  • 4. Williams RE. Healthy carriage of Staphylococcus aureus: its prevalence and importance. Bacteriol Rev. 1963; 27: 56-71[PubMed]
  • 5. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev. 1997; 10(3): 505-20[PubMed]
  • 6. Goslings WR, Buchli K. Nasal carrier rate of antibiotic-resistant staphylococci; influence of hospitalization on carrier rate in patients, and their household contacts. AMA Arch Intern Med. 1958; 102(5): 691-715[PubMed]
  • 7. Perl TM, Cullen JJ, Wenzel RP, Zimmerman MB, Pfaller MA, Sheppard D, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 2002; 346(24): 1871-7[DOI][PubMed]
  • 8. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001; 344(1): 11-6[DOI][PubMed]
  • 9. Kalmeijer MD, Coertjens H, van Nieuwland-Bollen PM, Bogaers-Hofman D, de Baere GA, Stuurman A, et al. Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study. Clin Infect Dis. 2002; 35(4): 353-8[DOI][PubMed]
  • 10. Bannerman TL, Peacock SJ, Murray PR, Baron EJ, Jorgensen JH, Landry ML, et al. Staphylococcus, Micrococcus, and other catalase-positive cocci. Man Clin Microbiol. 2006; 1: 390-411
  • 11. Schindler CA, Schuhardt VT. Lysostaphin: A New Bacteriolytic Agent for the Staphylococcus. Proc Natl Acad Sci. 1964; 51(3): 414-21[DOI]
  • 12. Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob Agents Chemother. 2003; 47(11): 3407-14[PubMed]
  • 13. Dajcs JJ, Hume EB, Moreau JM, Caballero AR, Cannon BM, O'Callaghan RJ. Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. Invest Ophthalmol Vis Sci. 2000; 41(6): 1432-7[PubMed]
  • 14. Patron RL, Climo MW, Goldstein BP, Archer GL. Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin. Antimicrob Agents Chemother. 1999; 43(7): 1754-5[PubMed]
  • 15. Bhakta M, Arora S, Bal M. Intraspecies transfer of a chloramphenicol-resistance plasmid of staphylococcal origin. Indian J Med Res. 2003; 117: 146-51[PubMed]
  • 16. Bastos M, Coutinho BG, Coelho MLV. Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications. Pharmaceuticals. 2010; 3(4): 1139-61[DOI]
  • 17. Farhangnia L, Ghaznavi-Rad E, Mollaee N, Abtahi H. Cloning, Expression, and Purification of Recombinant Lysostaphin From Staphylococcus simulans. Jundishapur J Microbiol. 2014; 7(5)[DOI][PubMed]
  • 18. Satishkumar R, Sankar S, Yurko Y, Lincourt A, Shipp J, Heniford BT, et al. Evaluation of the antimicrobial activity of lysostaphin-coated hernia repair meshes. Antimicrob Agents Chemother. 2011; 55(9): 4379-85[DOI][PubMed]
  • 19. Kiser KB, Cantey-Kiser JM, Lee JC. Development and characterization of a Staphylococcus aureus nasal colonization model in mice. Infect Immun. 1999; 67(10): 5001-6[PubMed]
  • 20. Schaffer AC, Solinga RM, Cocchiaro J, Portoles M, Kiser KB, Risley A, et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect Immun. 2006; 74(4): 2145-53[DOI][PubMed]
  • 21. Kokai-Kun JF, Walsh SM, Chanturiya T, Mond JJ. Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother. 2003; 47(5): 1589-97[PubMed]
  • 22. Klesius PH, Schuhardt VT. Use of lysostaphin in the isolation of highly polymerized deoxyribonucleic acid and in the taxonomy of aerobic Micrococcaceae. J Bacteriol. 1968; 95(3): 739-43[PubMed]
  • 23. Geary C, Stevens M. Rapid lysostaphin test to differentiate Staphylococcus and Micrococcus species. J Clin Microbiol. 1986; 23(6): 1044-5[PubMed]
  • 24. Wenzel RP, Perl TM. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect. 1995; 31(1): 13-24[PubMed]
  • 25. Quickel KJ, Selden R, Caldwell JR, Nora NF, Schaffner W. Efficacy and safety of topical lysostaphin treatment of persistent nasal carriage of Staphylococcus aureus. Appl Microbiol. 1971; 22(3): 446-50[PubMed]
  • 26. Faith RE, Montgomery CA, Durfee WJ, Aguilar-Cordova E, Wyde PR. The cotton rat in biomedical research. Lab Anim Sci. 1997; 47(4): 337-45[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments